Related Experiment Video

Updated: May 31, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Immunotherapeutic potential of oncolytic vaccinia virus

Steve H Thorne1

  • 1Department of Surgery and Department of Immunology, University of Pittsburgh Cancer Institute, University of Pittsburgh, 1.46e, Hillman Cancer Center, 5117 Centre Avenue, Pittsburgh, PA 15213, USA. ThorneSH@UPMC.edu

Immunologic Research
|July 1, 2011
PubMed

Insights

Oncolytic viruses, particularly vaccinia virus strains, show promise for cancer treatment due to their targeted spread and immune-stimulating capabilities. Next-generation vectors aim to enhance these dual mechanisms for improved therapeutic outcomes in cancer therapy.

Area of Science:

  • Virology
  • Immunotherapy
  • Oncology

Background:

  • Resurgent interest in oncolytic viruses for cancer treatment.
  • Advancements in next-generation vectors offer improved targeting and therapeutic potential.
  • Growing understanding of the immunotherapeutic capabilities of oncolytic viruses.

Purpose of the Study:

  • To discuss the development of next-generation oncolytic viral vectors.
  • To highlight the dual mechanisms of action: direct tumor lysis and immune stimulation.
  • To explore the potential of vaccinia virus as a backbone for oncolytic agents.

Main Methods:

  • Review of current research and clinical data on oncolytic viruses.
  • Analysis of vaccinia virus properties for oncolytic applications.
  • Discussion of strategies for enhancing vector targeting and immunogenicity.

Main Results:

  • Vaccinia virus demonstrates ideal characteristics for oncolytic virotherapy due to its replication and spread.
  • The virus's inherent immunomodulatory effects can be harnessed for enhanced anti-cancer immunity.
  • Next-generation vectors are being engineered to optimize these combined therapeutic effects.

Conclusions:

  • Oncolytic viruses, especially engineered vaccinia virus strains, represent a promising frontier in cancer immunotherapy.
  • Harnessing both the oncolytic and immunotherapeutic potential of viruses is key to developing effective cancer treatments.
  • Further development of next-generation vectors is crucial for maximizing therapeutic efficacy.

More Related Videos

A Simple and Efficient Approach to Construct Mutant Vaccinia Virus Vectors09:16

A Simple and Efficient Approach to Construct Mutant Vaccinia Virus Vectors

Published on: October 30, 2016

Production of High-Titer Recombinant Newcastle Disease Virus from Allantoic Fluid07:24

Production of High-Titer Recombinant Newcastle Disease Virus from Allantoic Fluid

Published on: May 25, 2022

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Vaccinations01:51

Vaccinations

Overview
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Immune Response Against Viral Pathogens01:29

Immune Response Against Viral Pathogens

The immune system's response to viral infections is a complex and coordinated process involving natural killer (NK) cells, T cell-mediated responses, and antibody-mediated responses.
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...